Iodoacetamide-induced sensitization of the pancreatic beta-cells to glucose stimulation.
At a glucose concentration of 3mm or less, iodoacetamide had no effect on the release of insulin from microdissected pancreatic islets of ob/ob-mice. At higher glucose concentrations, iodoacetamide exerted both an initial stimulatory and a subsequent inhibitory action. When islets were perifused with 1mm-iodoacetamide and 17mm-glucose the inhibitory action predominated after about 15min of transient stimulation. With decreasing concentrations of iodoacetamide the stimulatory phase was gradually prolonged, and with 0.003-0.1mm-iodoacetamide stimulation only was observed for 75min. Prolonged stimulation was also noted after a short pulse of iodoacetamide. Similar responses to 0.1mm-iodoacetamide were observed with islets from normal mice. With islets from ob/ob-mice the effect of 0.1mm-iodoacetamide was reproduced with 0.1mm-iodoacetate, whereas 0.1mm-acetamide had no apparent effect. Iodoacetamide increased the V(max.) of glucose-stimulated insulin release without altering the apparent K(m) for glucose. Leucine, glibenclamide or theophylline could not replace glucose in this synergistic action with iodoacetamide. Iodoacetamide rather inhibited the insulin-releasing action of theophylline. Iodoacetamide-induced potentiation of the glucose-stimulated insulin release was rapidly and reversibly inhibited by mannoheptulose, adrenaline, or calcium deficiency. The potentiating effect on insulin release was not paralleled by effects on glucose oxidation or on islet fructose 1,6-diphosphate. However, the inhibitory action of iodoacetamide might be explained by inhibition of glycolysis as evidenced by an inhibition of glucose oxidation and a rise of fructose 1,6-diphosphate. The results support our previous hypothesis that thiol reagents can stimulate insulin release by acting on relatively superficial thiol groups in the beta-cell plasma membrane. Glycolysis seems to be necessary in order for iodoacetamide to stimulate in this way.
D000577:Amides / Q000494:pharmacology; D000818:Animals; D002118:Calcium / Q000494:pharmacology; D002247:Carbon Isotopes; D004229:Dithiothreitol / Q000494:pharmacology; D004837:Epinephrine / Q000494:pharmacology; D005260:Female; D005636:Fructosephosphates / Q000378:metabolism; D005947:Glucose / Q000378:metabolism / Q000494:pharmacology*; D005905:Glyburide / Q000494:pharmacology; D066298:In Vitro Techniques; D007328:Insulin / Q000378:metabolism; D000078790:Insulin Secretion; D007456:Iodine Isotopes; D007461:Iodoacetates / Q000494:pharmacology*; D007515:Islets of Langerhans / Q000187:drug effects / Q000378:metabolism*; D007930:Leucine / Q000494:pharmacology; D008297:Male; D051379:Mice; D009765:Obesity / Q000235:genetics / Q000378:metabolism; D011863:Radioimmunoassay; D013806:Theophylline / Q000494:pharmacology; D014316:Tritium
D000577:Amides; D002247:Carbon Isotopes; D005636:Fructosephosphates; D007328:Insulin; D007456:Iodine Isotopes; D007461:Iodoacetates; D014316:Tritium; D013806:Theophylline; D007930:Leucine; D005947:Glucose; D005905:Glyburide; D002118:Calcium; D004229:Dithiothreitol; D004837:Epinephrine